Librería Servicio Médico

Author : A. Roth / Ki Hong / U. Komaki

Language: English

Finishing : Hardcover, 616 pages

ISBN : 978-1-118-46874-6

Edition Number: 2014

Author Information:

Jack A. Roth, MD, F.A.C.S., is Professor and Bud Johnson Clinical Distinguished Chair in the Department of Thoracic and Cardiovascular Surgery, Professor of Molecular and Cellular Oncology, Director of the W.M. Keck Center of Innovative Cancer Therapies, and Chief of the Section of Thoracic Molecular Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas, USA.

James D. Cox, MD, is Professor and Head of the Department of Radiation Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas, USA.

Waun Ki Hong, MD, D.M.Sc. (Hon.), is the American Cancer Society Professor and Samsung Distinguished University Chair in Cancer Medicine, as well as Professor and Head of the Division of Cancer Medicine and Professor in the Department of Thoracic/Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas, USA.

Description:

The best and most concise single source for state-of-the-art diagnosis and treatment of lung cancer –newly revised, updated, and expanded.

Lung cancer has long been the number-one cause of death from cancer every year and the third most frequently diagnosed after breast and prostate cancers. In 2010, about 15% of all cancer diagnoses and 30% of all cancer deaths were due to lung cancer. Needless to say, there is a great need for more rapid advancements in diagnosis and treatment of this devastating disease.

Here is the comprehensively revised, updated, and expanded edition of the well-established, evidence-based reference book that deals with the most recent advances in lung cancer prevention, screening, diagnosis, research, and treatment for the clinician. Edited and authored by leading authorities in the field, this Fourth Edition of the highly regarded Lung Cancer is better than ever –featuring nine new chapters along with seven re-formatted ones that are nearly brand new in content and approach. It covers Smoking Prevention and Cessation; Molecular Profiling; Somatic Genome Alterations in Human Lung Cancers; Management of Multi-Focal Bronchioloalveolar Carcinoma (BAC); Primary Tracheal Tumors; Predictive Tumor Biomarkers for EGFR Inhibitors; Non-Small Cell and Small-Cell Lung Carcinoma; and more.

This Fourth Edition of Lung Cancer:

• Provides the very latest research in the identification of biomarkers to predict a high risk for developing lung cancer – vital for implementing screening, diagnosis, and prevention strategies
• Presents the newest lung cancer staging system, as well as updated and cutting-edge surgical and radiation therapy techniques that make local tumor control more effective and less invasive while sparing normal tissues
• Discusses combined modality therapy and new chemotherapeutic agents which are yielding higher response rates and improved survival when used in the adjuvant setting or concurrent with highly sophisticated radiation or proton treatment
• Offers novel and emergent approaches to preventative, diagnostic, and therapeutic modalities with an emphasis on the best evidence available from the latest studies and clinical trials

With almost half of the revised and updated content being brand new, Lung Cancer, Fourth Edition, is an important and vital resource for all medical professionals and students involved in the care and treatment of those struck with this catastrophic illness.

Table Of Contents:

• Contributors, viii
• Preface, xiii
• 1 Smoking Prevention and Cessation, 1
• Alexander V. Prokhorov and Karen Suchanek Hudmon
• 2 Lung Cancer Susceptibility and Risk Assessment Models, 25
• Xifeng Wu, Xia Pu, and Jie Lin
• 3 Molecular Profiling, 48
• Lauren Averett Byers
• 4 Somatic Genome Alterations in Human Lung Cancers, 67
• Marcin Imielinski, Peter S. Hammerman, Roman Thomas, and Matthew Meyerson
• 5 Serum Proteomic Biomarkers, 90
• Mohamed Hassanein and David P. Carbone
• 6 Molecular Biology of Lung Preneoplasia, 110
• Humam Kadara and Ignacio I. Wistuba
• 7 Detection and Treatment of Preneoplastic Lesions, 129
• Rachel Jen and Stephen Lam
• 8 Pathology of Adenocarcinoma, 144
• William D. Travis
• 9 Management of Multifocal Bronchioloalveolar Carcinoma (BAC), 158
• Howard West
• 10 Radiology and Lung Cancer Screening, 176
• Patricia de Groot and Reginald F. Munden
• 11 Imaging Lung Cancer, 191
• Sonia L. Betancourt Cuellar, Edith M. Marom, and Jeremy J. Erasmus
• 12 Staging of the Mediastinum, 202
• Mauricio Pipkin and Shaf Keshavjee
• 13 Management of the Solitary Pulmonary Nodule, 214
• Min P. Kim
• 14 Minimally Invasive Resections for Lung Cancer, 224
• Shanda H. Blackmon
• 15 Extended Resections for Lung Cancer, 236
• Matthew A. Steliga and David C. Rice
• 16 Bronchoscopic Interventions for Lung Cancer, 253
• Donald R. Lazarus and George A. Eapen
• 17 Primary Tracheal Tumors, 267
• Francesco Sammartino and Paolo Macchiarini
• 18 Adjuvant Chemotherapy Following Surgery for Lung Cancer, 278
• Kathryn A. Gold
• 19 Neoadjuvant Chemotherapy for Resectable Non-Small Cell Lung Cancer, 290
• Christopher G. Azzoli and Katherine M.W. Pisters
• 20 Image-Guided Radiation Therapy, 309
• Kenneth E. Rosenzweig and Sonal Sura
• 21 Stereotactic Ablative Radiotherapy for Lung Cancer, 320
• Puneeth Iyengar and Robert D. Timmerman
• 22 Proton Therapy, 338
• Joe Y. Chang and James D. Cox
• 23 Combinations of Radiation Therapy and Chemotherapy for Non-small Cell and Small-Cell Lung Carcinoma, 353
• Daniel Gomez, Zhongxing Liao, Pierre Saintigny, and Ritsuko U. Komaki
• 24 Individualized Radiotherapy by Dose Escalation and Altered Fractionation in Non-small Cell Lung Cancer, 379
• Heath D. Skinner, Ritsuko U. Komaki, Joe Y. Chang, and James D. Cox
• 25 Molecular Target Treatment for Personalized Radiotherapy in Lung Cancer, 390
• Steven H. Lin and Ritsuko U. Komaki
• 26 EGFR Tyrosine Kinase Inhibitors and Monoclonal Antibodies: Clinical Trial Review, 406
• Kathryn F. Mileham, Edward S. Kim, and William N. William Jr
• 27 Mechanisms of Resistance to Epidermal Growth Factor Receptor (EGFR) in Non-small Cell Lung Cancer, 421
• Erminia Massarelli
• 28 Predictive Tumor Biomarkers for EGFR Inhibitors, 435
• Lucia Kim, Geoffrey Liu, and Ming-Sound Tsao
• 29 Immunologic Approaches to Lung Cancer Therapy, 454
• Jay M. Lee, Steven M. Dubinett, and Sherven Sharma
• 30 Novel and Emerging Agents in NSCLC, 464
• Anne S. Tsao and Jack A. Roth
• 31 Novel Clinical Trial Designs for Metastatic Lung Cancer, 479
• Vassiliki A. Papadimitrakopoulou
• 32 Novel Statistical Models for NSCLC Clinical Trials, 488
• J. Jack Lee and Caleb T. Chu
• 33 Tumor Microenvironment, Angiogenesis Biology, and Targeted Therapy, 505
• John V. Heymach and Tina Cascone
• 34 Anti-angiogenic Agents in Metastatic NSCLC, 527
• Millie Das and Heather Wakelee
• 35 Targeting ALK Rearrangements, 541
• Justin F. Gainor and Alice T. Shaw
• 36 Non-small Cell Lung Cancers (NSCLC) with Mutations in BRAF, 557
• Renata Ferrarotto and George R. Simon
• 37 Prognostic and Predictive Biomarker Signatures, 564
• Johannes R. Kratz and David M. Jablons
• 38 Brain Metastasis from Lung Cancer, 572
• Ritsuko U. Komaki and Amol J. Ghia
• Index, 591
• Color plate section between pages 146 and 147

Valoración:

¡Sea el primero en dejar un comentario!

Nuevo Comentario